All stocks / INBP
INTEGRATED BIOPHARMA INC INBP
Integrated Biopharma (INBP): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- INTEGRATED BIOPHARMA INC
- Market tier
- OTCQX US
- Trading status
- Active
- Last trade
- Nov 16
News headlines
The financial report, and what it means
Annual figures to 2026-06-30- Net loss
- ($2,842,000)
It spends more than it earns
Under strainThe company lost $2.8 million in the year. It reported no sales.
- Cash and cash equivalents
- $4,471,000
- Net cash from operating activities
- $1,241,000
The business brings in cash
SteadyDay-to-day business added $1.2 million in cash over the year. It had $4.5 million in the bank.
- Total assets
- $25,338,000
- Total liabilities
- $7,671,000
It owns more than it owes
SteadyEverything the company owns adds up to $25.3 million. Its debts and unpaid bills add up to $7.7 million. That is about $0.30 owed for every $1 owned.
What this adds up to
1 of 3 checks show strain. It spends more than it earns. These are facts from the company's own reports, not a recommendation.
Signals
Estimated float about 18,187,885 shares as of 2026-11-13: 31,059,610 outstanding minus 12,871,725 held by 3 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
| 2026-11-13 | 10-Q | FORM 10-Q |
| 2026-11-13 | 8-K | FORM 8-K |
| 2026-10-28 | DEF 14A | FORM DEF 14A |
| 2026-09-25 | 10-K | FORM 10-K |
| 2026-09-25 | 8-K | FORM 8-K |
| 2026-08-20 | 8-K | FORM 8-K |
| 2026-07-02 | 8-K | FORM 8-K PNC FIRST AMENDMENT |
| 2026-06-25 | 4 | PRIMARY DOCUMENT |
| 2026-06-25 | 4 | PRIMARY DOCUMENT |
| 2026-06-25 | 4 | PRIMARY DOCUMENT |
| 2026-06-25 | 4 | PRIMARY DOCUMENT |
| 2026-06-25 | 4/A | PRIMARY DOCUMENT |
Common questions about INBP
Does INBP file reports with the SEC?
Yes. Integrated Biopharma files with the SEC under company number 0001016504. The most recent filing we hold is a 10-Q dated 2026-11-13.
Source recordHow many INBP shares are outstanding?
31,059,610 shares as of 2026-11-13, as reported to the SEC.
Source recordHas INBP filed reports late?
We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.
Who runs Integrated Biopharma?
Officers named in its insider filings: Christina Kay (Co-Chief Executive Officer), Dina Masi (Chief Financial Officer) and Sheppard Riva (Co-Chief Executive Officer).
Source recordIs Integrated Biopharma making money?
The company lost $2.8 million in the year. It reported no sales. (Annual figures to 2026-06-30. Facts from the company's own report, not a recommendation.)
Source record